What is CRSP's current stock price?

As of now, CRSP is trading at $48.83, with a daily change of -3.73%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

CRSP CRSP Badge

CRISPR Therapeutics

$48.83

-$1.90 | -3.73%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$78.48

MKT CAP

$4.65B

52W Low

$30.06

VOL

$1.63M

P/E Ratio

N/A

AVG VOL

$2.57M

RSI

TREND

CRSP Stock IQ

Login to see CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CRSP Target Price

Login to display

Strengths

CRSP Rewards

Earnings are forecast to grow

CRSP Rewards

Upgraded on attractively valued

CRSP Rewards

Outperform the market

CRSP Rewards

Investors confidence is positive

Chart

$72.32 (-32.48%)

$54.13 (-9.79%)

$47.49 (+2.82%)

$55.15 (-11.46%)

1year

6month

3month

1month

CRSP Risk Level

CRSP has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Moderate

LOW

HIGH

CRSP Analysts Opinion

CRSP overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

CRSP Analysts Opinion

CRSP Analysts opinion is negative but has improved from the past 3 months

CRSP Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

71%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

67%

50%

CRSP Street Sentiment

CRSP Street Sentiment is bullish but have mixed views on the near-term outlook

CRSP Performance Sentiment

Sentiments overview associated with CRSP events and the stock performance.

71%

25%

Positive

Negative

17 out of 24
events present

6 out of 24
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$52.44

Resistance
Price

$49.36

Current Price Range

$76.78

Show methods +

Linked to CRSP

IQ

Close Price

Change

VCEL

4.04

38.11

-2.16%

IBRX

3.89

2.03

-4.68%

CLDI

3.50

1.37

-4.86%

BNTX

3.32

98.02

-3.37%

AMGN

4.03

337.81

-1.34%

CRSP Latest Analysis +

RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50 Keeps Sector Perform. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11 RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares. The analysts noted that CASGEVY CRISPRs leading product missed [….]

Tue Nov 18, 2025

$53.47 | -3.34%

Potential

Notable Monday Option Activity: CRSP STZ AVGO. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in CRISPR Therapeutics AG (Symbol: CRSP) where a total of 12088 contracts have traded so far representing approximately 1.2 million underlying shares. That amounts to ab

Mon Nov 17, 2025

$55.32 | +5.31%

Momentum

Crispr Therapeutics gains amid takeover speculation.

Mon Nov 17, 2025

$55.32 | +5.31%

Activity

DYAI: Purchase Orders Rolling In. By Dyadic Applied BioSolutions Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th 2025 and held a conference call to discuss them after that days market close. The remarkable takeaway from the press release is that Dyadic has a diversified set of revenue opportunities that may all contribute to the topline in the next few months. Customers have submitted purchase orders for C1 and Dapibus produced proteins including cell culture media and m

Fri Nov 14, 2025

$52.44 | +2.66%

Activity

Citigroup Maintains CRISPR Therapeutics (CRSP) Buy Recommendation. Fintel reports that on November 12 2025 Citigroup maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 57.77% Upside

Thu Nov 13, 2025

$51.11 | -2.07%

Rating

ARK Sold Almost 400000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? . Key PointsArk Investment sold 395617 shares worth about $25 million.

Wed Nov 12, 2025

$52.19 | -5.47%

Activity

Potential

CRISPR Therapeuticss Options Frenzy: What You Need to Know. Whales with a lot of money to spend have taken a noticeably bearish stance on Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades.If we consider the specifics of each trade it is accurate to state that 7% of the investors opened trades with ish expectations and 84% with bearish.From the overall spotted trades 3 are puts for a total amount of $220010 and 10 calls for a total amount of $579566.Based on t

Tue Nov 11, 2025

$55.21 | +1.15%

Activity

Potential

CRISPR Therapeutics Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial. On Saturday CRSP) shared Phase 1 data from its ongoing clinical trial evaluating CTX310 an investigational in vivo CRISPR/Cas9 gene-editing .ANGPTL3 or Angiopoietin-Like 3 is a protein primarily produced in the liver that plays a major role in regulating blood lipid (fat) levels particularly .A single-course treatment with CTX310 produced dose-dependent durable reductions in circulating ANGPTL

Tue Nov 11, 2025

$55.21 | +1.15%

Activity

CRSP Posts Narrower-Than-Expected Loss in Q3 Sales Miss Estimates. CRISPR Therapeutics posts a narrower-than-expected Q3 loss trims R&D spend and advances late-stage and next-gen gene-editing programs.

Tue Nov 11, 2025

$55.21 | +1.15%

Earnings

Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged. Crispr stock reversed lower Monday while Intellia stock surged on promising updates for their gene-editing efforts.The post Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged appeared first on Investor'.s Business Daily.

Mon Nov 10, 2025

$54.58 | -0.98%

Momentum

FAQ About CRSP Stock Insights

What is CRSP current stock price?

What are CRSP stock strengths?

What is CRSP Risk Level?

What is CRSP market cap and volume?

What is CRSP current Stock IQ?

Should I buy CRSP stock right now?

Is CRSP a Strong Buy right now?

What does a 'Strong Buy' rating mean for CRSP?

What does a 'Strong Sell' rating mean for CRSP?

What factors influence CRSP's Stock IQ?

Explore our CRSP Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored CRSP Stock Strategies
Effective Risk Management

FIND US ON

Receive our CRSP Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

CRSP CRSP Badge

CRISPR Therapeutics

Current Price

$48.83

-$1.90 | -3.73%

52W High

$78.48

MKT CAP

$4.65B

52W Low

$30.06

VOL

$1.63M

P/E Ratio

N/A

AVG VOL

$2.57M

RSI

TREND

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

CRSP Rewards

Earnings are forecast to grow

CRSP Rewards

Upgraded on attractively valued

CRSP Rewards

Outperform the market

CRSP Rewards

Investors confidence is positive

Linked to CRSP

Symbol

IQ

Close

Change

VCEL

4.04

38.11

-2.16%

IBRX

3.89

2.03

-4.68%

CLDI

3.50

1.37

-4.86%

BNTX

3.32

98.02

-3.37%

AMGN

4.03

337.81

-1.34%

CRSP Stock IQ

Login to unlock CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$72.32 (-32.48%)

$54.13 (-9.79%)

$47.49 (+2.82%)

$55.15 (-11.46%)

1year

6month

3month

1month

CRSP Analysts Opinion

CRSP Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

CRSP Analysts Opinion

CRSP Analysts opinion is negative but has improved from the past 3 months

CRSP Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

71%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

67%

50%

CRSP Street Sentiment

CRSP Street Sentiment is bullish but have mixed views on the near-term outlook

CRSP Risk Level

CRSP has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Moderate

LOW

HIGH

CRSP Performance Sentiment

Sentiments overview associated with CRSP events and the stock performance.

71%

25%

Positive

Negative

17 out of 24
events present

6 out of 24
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$52.44

Resistance
Price

$49.36

Current Price Range

$76.78

Show methods +

CRSP Latest Analysis

RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50 Keeps Sector Perform. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11 RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares. The analysts noted that CASGEVY CRISPRs leading product missed [….]

Tue Nov 18, 2025

$53.47 | -3.34%

Potential

Notable Monday Option Activity: CRSP STZ AVGO. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in CRISPR Therapeutics AG (Symbol: CRSP) where a total of 12088 contracts have traded so far representing approximately 1.2 million underlying shares. That amounts to ab

Mon Nov 17, 2025

$55.32 | +5.31%

Momentum

Crispr Therapeutics gains amid takeover speculation.

Mon Nov 17, 2025

$55.32 | +5.31%

Activity

DYAI: Purchase Orders Rolling In. By Dyadic Applied BioSolutions Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th 2025 and held a conference call to discuss them after that days market close. The remarkable takeaway from the press release is that Dyadic has a diversified set of revenue opportunities that may all contribute to the topline in the next few months. Customers have submitted purchase orders for C1 and Dapibus produced proteins including cell culture media and m

Fri Nov 14, 2025

$52.44 | +2.66%

Activity

Citigroup Maintains CRISPR Therapeutics (CRSP) Buy Recommendation. Fintel reports that on November 12 2025 Citigroup maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 57.77% Upside

Thu Nov 13, 2025

$51.11 | -2.07%

Rating

ARK Sold Almost 400000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? . Key PointsArk Investment sold 395617 shares worth about $25 million.

Wed Nov 12, 2025

$52.19 | -5.47%

Activity

Potential

CRISPR Therapeuticss Options Frenzy: What You Need to Know. Whales with a lot of money to spend have taken a noticeably bearish stance on Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades.If we consider the specifics of each trade it is accurate to state that 7% of the investors opened trades with ish expectations and 84% with bearish.From the overall spotted trades 3 are puts for a total amount of $220010 and 10 calls for a total amount of $579566.Based on t

Tue Nov 11, 2025

$55.21 | +1.15%

Activity

Potential

CRISPR Therapeutics Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial. On Saturday CRSP) shared Phase 1 data from its ongoing clinical trial evaluating CTX310 an investigational in vivo CRISPR/Cas9 gene-editing .ANGPTL3 or Angiopoietin-Like 3 is a protein primarily produced in the liver that plays a major role in regulating blood lipid (fat) levels particularly .A single-course treatment with CTX310 produced dose-dependent durable reductions in circulating ANGPTL

Tue Nov 11, 2025

$55.21 | +1.15%

Activity

CRSP Posts Narrower-Than-Expected Loss in Q3 Sales Miss Estimates. CRISPR Therapeutics posts a narrower-than-expected Q3 loss trims R&D spend and advances late-stage and next-gen gene-editing programs.

Tue Nov 11, 2025

$55.21 | +1.15%

Earnings

Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged. Crispr stock reversed lower Monday while Intellia stock surged on promising updates for their gene-editing efforts.The post Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged appeared first on Investor'.s Business Daily.

Mon Nov 10, 2025

$54.58 | -0.98%

Momentum

Discover CRSP Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of CRSP. We're here to help you make informed investment decisions today.

FIND US ON

Receive our CRSP Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CRSP Stock trends

CRSP Stock performance

CRSP Stock analysis

CRSP investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CRSP

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CRSP

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

CRSP Stock IQ

CRSP Target Price

CRSP Risk Level

CRSP Analysts Opinion

CRSP Street Sentiment

CRSP Performance Sentiment

Technical Price Levels

Explore our CRSP Stock insights

Receive our CRSP Daily Alerts

CRSP Stock IQ

CRSP Street Sentiment

CRSP Risk Level

Technical Price Levels

Discover CRSP Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of CRSP. We're here to help you make informed investment decisions today.

Receive our CRSP Daily Alerts

CRSP Runner Alarm